CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - CorMedix Therapeutics will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30pm PST [1][2] Company Overview - CorMedix Therapeutics is focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company is commercializing DefenCath® for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter [2] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN®, REZZAYO®, VABOMERE®, ORBACTIV™, BAXDELA®, and KIMYRSA®, as well as TOPROL-XL® [2] Clinical Studies and Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations [3] - The company intends to develop DefenCath as a catheter lock solution for use in other patient populations [3] - REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic bone marrow transplantation (BMT) [3] - Topline results of the Phase III study for REZZAYO are expected in Q2 2026 [3]